|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01011 NT PHARMA
Nominal 
0.740 -0.010 (-1.333%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 11,995 | -61.674% | 37,960 | 7,366 | 207,092 | 226,699 |
| Cost of Sales | (1,983) | -92.251% | (32,700) | -- | (81,806) | (81,240) |
| Gross Profit | 10,012 | 75.464% | 5,260 | -- | 125,286 | 145,459 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | (78) | -- | |
| Change in FV & Impairment on Others | (2,218) | -- | (5,922) | -- | -- | (14,011) | |
| Profit / (Loss) on Disposal | -- | -- | -- | 12,272 | -- | -- | |
| Other Non-operating Items | -- | -- | (7,009) | -- | (11,318) | (5,807) | |
| Share of Results of Asso. & JCEs | 0 | -- | 10,244 | 37,039 | 9,003 | 34,490 | |
| Profit / (Loss) before Taxation | (16,906) | -- | (53,480) | (33,369) | (54,296) | (148,752) | |
| Taxation | 0 | -- | 123 | (122) | (12,109) | (2,582) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | (110,099) | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 1,796 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (16,906) | -- | (53,357) | (143,590) | (66,405) | (149,538) | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 14,592 | 143.078% | 31,533 | 28,809 | 71,710 | 88,488 |
| Depreciation & Amortisation | 318 | -37.769% | 660 | 1,213 | 21,070 | 42,249 |
| Directors' Emoluments | -- | -- | 1,938 | 2,231 | 3,609 | 3,774 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Disclaimer | Disclaimer | Disclaimer | Disclaimer |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -3.030 | -- | -20.200 | -60.200 | -34.900 | -79.100 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.034) | 0.212 | 0.191 | (0.072) |
| NBV per share ($) | (0.411) | -- | (1.511) | (1.286) | (1.269) | (1.109792) |
| Remarks: | Real time quote last updated: 22/08/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -16,906 |
| %Change | -- |
| EPS / (LPS) | RMB -0.030 |
| NBV Per Share (¥) | RMB -0.411 |